Ganglioside stimulated neurite outgrowth may be due to ganglioside binding to membrane proteins or to intercalation into the membrane. To test that ganglioside binding proteins could be found on neuronal surfaces, antiidiotypic ganglioside monoclonal antibodies (AIG mAbs) were generated to mimic the biological properties of the GM1 ganglioside. The AIG mAbs were identified by their ability to bind to a known GM1 binding protein, the p-subunit of cholera toxin. For the two AIG mAbs studied, AIG5 and AIG20, binding to P-CT was blocked most strongly by GM1. This data also suggests that AIG5 and AIG20 mimic different but overlapping epitopes of the ganglioside GM1. Western blotting and immunoprecipitation of mammalian tissues reveals four potential ganglioside binding proteins of molecular weight 93, 66, 57, and 45 kDa. Immunocytochemistry demonstrates neuronal surface label with the AIG mAbs, which suggests that gangliosides, enriched on the neuronal surface membrane, are co-localized with putative ganglioside binding proteins. In bioassays, the AIG mAbs promote neuronal sprouting. This shows that these antibodies can be used to study the biological effects of ganglioside binding to neuronal surface proteins, and the role of gangliosides in the activation of neurite outgrowth.
Gangliosides have the ability to affect nervous system development and regeneration. This idea was first proposed following a study of pathological gangliosidosis. In this disease, gangliosides accumulate in the brain, and affected neurons begin to sprout aberrant neurites (Purpura and Baker, 1977; Walkley and Siegel, 1985) . Later studies into the effects of exogenously added gangliosides confirmed that gangliosides have the ability to induce neurite growth in vivo (Gorio et al, 1980) and in vitro (Roisen et al, 1981) . The hypothesis that gangliosides may mediate the growth activity of neurons is supported by the observations that gangliosides are enriched on the neuronal membrane, and that their pattern of regional and subcellular distribution changes dramatically during development and aging (Suzuki, 1965; Yates, 1986) .
Gangliosides are a class of glycolipids that have been suggested to mediate many cellular activities. Because gangliosides are enriched on the outer leaflet of the cell membrane, gangliosides are in a position to interact with extracellular ligands or molecules of the cell surface. Such molecules can be located on the same cell or an adjacent cell. The location of the gangliosides allow them to mediate cell-cell recognition, cell proliferation, and differentiation (Hakomori, 1986) . These activities occur via changes in membrane structure and fluidity as well as through the modulation of the membrane receptors, second messenger transducers, and transporters (Igarashi et al, 1989) .
The molecular site of ganglioside action is not known although there are two hypotheses for which there is extensive evidence. Either the gangliosides bind to membrane proteins to activate them directly or the gangliosides intercalate into the plasma membrane to alter membrane fluidity and activate membrane proteins indirectly (Ledeen, 1984; Hakomori, 1990; Schnaar, 1991) .
Ganglioside mediated cellular activity can occur via interactions with membrane proteins (Schengrund, 1990 ) such as growth factor receptors (Schwartz and Spirman, 1982; Mutoh et al., 1995) or receptors modulating cell adhesion (Barletta et al., 1991) . Evidence from primary neuronal cells and nonneuronal cell lines strongly implicates binding to the receptor as the mode of ganglioside action (Bremer et al., 1984 (Bremer et al., , 1986 Cheresh and Klier, 1986; Cheresh et al, 1987; Mugnai et al., 1988; Stallcup, 1988; Stallcup et al., 1989; Weis and Davis, 1990; Song et al, 1993; Van Brocklyn et al, 1993) . In support of this possibility, several ganglioside binding proteins have been identified (Tiemeyer et al, 1989 (Tiemeyer et al, , 1990 Chan and Liu, 1991; Siegel and Suzuki, 1994) . Further evidence for this hypothesis comes from the work that has shown that the ganglioside GQlb interacts directly with neuronal cell surface proteins to stimulate phosphorylation of membrane proteins and neuritogenesis (Tsuji et al, 1988 (Tsuji et al, , 1992 Nakaoka et al, 1992; Nagai, 1995) .
We wanted to known whether ganglioside binding to a membrane protein was sufficient to modulate neuronal activity. This study of the molecular site of ganglioside action has been hampered by the lack of probes that recognize ganglioside binding proteins as well as modulate function in bioassays. Gangliosides can be labeled and used for binding studies (Tiemeyer et al, 1989 (Tiemeyer et al, , 1990 Chan and Liu, 1991; Pacuszka and Fishman, 1992) . However, gangliosides are hydrpphobic and will not perform as well as protein reagents in many assays that are used to identify and purify ligands. In addition, complexing gangliosides to a carrier protein alters biological activity, preventing their use in a biological assay (Tiemeyer et al, 1989 (Tiemeyer et al, , 1990 . Purified gangliosides used in bioassays are subject to aggregation, micelle formation, sequestration by media components such as albumin, and intercalation into the cell membranes of the cells used in a bioassay.
To determine the molecular site of action requires a probe that retains the biochemical and functional features of gangliosides, but with the caveat that the probe cannot intercalate into the membrane. In addition, die probe would be required to bind a known ganglioside binding protein in a manner that can be competed by a ganglioside. This probe must also be amenable to use in biological assays.
These criteria can be satisfied by a particular type of anti-body called an anti-idiotypic antibody. To describe what an anti-idiotypic antibody is, consider that an antibody that is generated in response to an antigen is called an idiotypic antibody. This idiotypic antibody is present in the body to recognize and bind to foreign antigens in order to tag them for removal. In response to the presence of the idiotypic antibody, the humoral immune system produces an anti-idiotypic antibody. The anti-idiotypic antibody is thought to act as a template for the further production of idiotypic antibodies, which insures a constant source of antibodies to fight foreign infection (Jerne, 1974) . In other words, an anti-idiotypic antibody is an antibody that is generated to an idiotypic antibody. Experimentally, anti-idiotypic antibodies have been generated to investigate cell surface receptor function (Gaulton et ai, 1985) . For these experiments, a ligand is used to generate an idiotypic antibody. The idiotype then serves as the immunogen for the subsequent generation of an anti-idiotypic antibody. Just as the idiotypic antibody binds to the ligand, the anti-idiotypic antibody binds to the receptor. An example of this principle is shown in Figure 1 .
To test whether gangliosides act by binding to a receptor in the neuronal cell membrane, we have generated an antiidiotypic antibody to the ganglioside GM1. These antiidiotypic mAbs are proteinaceous probes of ganglioside activity that do not intercalate into the plasma membrane. In addition, they can be used in bioassays to determine the molecular site of ganglioside activity.
Here we describe the characterization of this antibody as well as the results of a bioassay to determine whether this antibody has a physiological effect on neuronal sprouting. The experiments described here show that the anti-idiotypic ganglioside antibodies mimic the biochemical properties of gangliosides. This and other tests have demonstrated that the antibodies are anti-idiotypic ganglioside (AIG) monoclonal antibodies (mAbs) that bear the internal image of an idiotypic anti-GMl antibody. The AIG mAbs retain the biological features of the ganglioside GM1 in biochemical assays. In addition, these antibodies can mimic ganglioside activity in in vivo neuronal sprouting bioassays. The ability of AIG mAbs to promote sprouting in bioassays suggests that GM1 can exert its effects by binding to membrane proteins, which leads to neuronal sprouting in the absence of membrane intercalation.
Results
The goal of this study was to determine whether an antibody could mimic the biological activity of the ganglioside GM1. An antibody that was a true mimic of GM1 activity must bind to a known GM1 binding protein in a manner that could be competed by GM 1. The anti-idiotypic nature of the antibody is conferred by the ability to bind to an idiotypic anti-GMl antibody. The AIG mAb must also exhibit the ability to recognize putative ganglioside binding proteins by anatomical and biochemical methods. The biological activity of the antibodies was tested in a bioassay of neurite sprouting using primary neurons.
Identifying monoclonal anti-idiotypic antibodies to gangliosides
We have generated anti-idiotypic monoclonal antibodies to gangliosides (AIG mAbs) by using an immunosuppressant to stimulate antibody production toward the ganglioside GM1.
This method was used because gangliosides are normally poor immunogens. Among the hybridomas generated, the AIG mAbs were selected by enzyme linked immunosorbent assays (ELISAs) according to their ability to bind to the (3-subunit of cholera toxin (P-CT), a known GM1 binding protein. Antibodies that bound to lipid extracts of brain, purified asialo-GMl, purified gangliosides (GM1, GM2, GM3, GDI a, GDlb, or GTlb), a mixture of bovine brain gangliosides, or galactocerebroside were eliminated from further screening.
The next assay was used to identify which antibodies have the ability to recognize potential ganglioside binding proteins within the nervous system. The selected antibodies were tested for their ability to bind to brain homogenates in ELISAs. The antibodies that bound the P-CT and brain homogenates were tested simultaneously in competitive binding assays using dot blots and ELISAs. From these studies, two monoclonal antibodies, AIG5 and AIG20, were chosen for further study; the results from these assays are described in detail below.
To assess the specificity of binding of the AIG mAbs, binding to p-CT was challenged by the addition of individual gangliosides. For both AIG mAbs, binding to P-CT was inhibited most strongly in the physiologically relevant range of 0-1000 nM by GM1 (Figure 2 ). The ganglioside GTlb was the only other ganglioside able to inhibit AIG mAb binding to P-CT. The IC 50 values for AIG mAb binding (i.e., the concentration of ganglioside required to inhibit antibody binding to 1000 ng/100u,l/well P-CT [-170 nM] by 50%) in this range was calculated (Table I) for the inhibitable portion of the curve. An unrelated IgM monoclonal antibody, EA1B1, and conditioned media from NS1 myeloma cells (NS1 cm) were used as controls for nonspecific antibody binding to P-CT. The control antibody EA 1B1 was chosen because it binds to the surface of neurons, making it an excellent control antibody for later bioassays. Control antibody binding was weak and was not effected by the addition of gangliosides to the assay.
Both A1G5 and AIG20 bound to homogenates of embryonic hippocampal neurons on dot blots; this binding could be inhibited by GM1. The AIG mAbs were of the IgM subclass. One of these antibodies strongly bound to a commercially available idiotypic anti-GM 1 antibody in ELISA assays which confirmed that AIG5 is an anti-idiotypic antibody to GM1 (Figure 3 ).
Distribution and identification of antigens of interest
If gangliosides act by binding to cellular proteins, the AIG mAbs should bind to these proteins in sections of tissue. Immunocytochemistry revealed that the AIG mAbs labeled the surfaces of cortical cells, pyramidal neurons of the hippocampal CA cell fields (Figure 4a, b) , and the Purkinje cells of the cerebellum as well as perinuclear membranes likely to be Golgi bodies or endoplasmic reticulum. The cell surface and intracellular membranes of skeletal muscle were also labeled (Figure 4d ,e). Tissues were not labeled by the control NS1 cm (Figure 4c ,f). The AIG mAbs also labeled cells in the spinal cord, sciatic nerve, heart, gut, liver, and adrenal gland but not in thymus. In addition, the surfaces of primary embryonic hippocampal cells in culture were labeled by AIG mAbs.
The identification of putative ganglioside binding proteins
To further identify the proteins that are recognized by AIG mAbs, Western blots of tissue homogenates were probed with the antibodies. Both AIG mAbs recognize four predominant
Fig. 1. A model describing anti-idiotypic antibodies. We hypothesize that the ganglioside GMl binds to putative membrane proteins to modulate their activity (a). To test this hypothesis, we have used GM1 as an antigen for the production of idiotypic GMl antibodies (b) which in turn become antigens for the endogenous production of anti-idiotypic GMl antibodies directed to the functional site of idiotypic GM 1 antibodies (c). Although this may be a rare event in the normal animal, cyclophosphamide disrupts the normal immune regulation to enhance the production of idiotypic and anti-idiotypic GMl antibodies. These anti-idiotypic antibodies can bind to putative GMl binding proteins as a model of GMl activity, and can be used to identify ganglioside binding proteins (d).
[GDla] nM Fig. 2 . Gangliosides block AIG antibody binding to P-CT. The specificity of the anti-idiotypic (AIG) antibodies for p-cholera toxin was tested using a blocking assay. fi-CT (1000 ng) was adsorbed onto ELISA plates and incubated with gangliosides for 2 h at 37°C. Purified AJG antibodies were added in the presence of gangliosides. Antibody binding was visualized using HRP labeled secondary antibodies reacted with PPDA. The amount of antibody binding was measured as absorbance at 405 nM. Each of the AIG antibodies, and a control IgM antibody (EA1BI), competed for P-CT binding with the gangliosides GMl (a), asialo-GMl (b), GTlb (c), GM2 (d), GM3 (e), GDla (f), and GDIb (g). The values graphed are the means of duplicate samples and their corresponding standard deviations (SD) The SD for most values is very small so that the SD bar is obscured by the symbols for the data. ICJQ values demonstrate the ability of gangliosides to block AIG antibody binding to (3-CT. The data in the linear range of ganglioside blocking (0-1000 nM of ganglioside) displayed in figure 2 was fit by linear regression, and used to determine the IC^ (the nanomolar concentration of ganglioside needed to inhibit antibody binding to 1000 ng p-CT adsorbed to plastic wells by 50%). The dash represents the finding that GTlb at 0-1000 nM had little or no effect on antibody binding to (3-CT. The IC^ is expressed as a nanomolar value.
bands at approximately 93, 66, 57, and a doublet at 45 kDa in Western blots of embryonic hippocampal neurons ( Figure 5 ). These bands are also labeled in Western blots of rat skeletal muscle and normal human hippocampus. These antibody binding proteins are found in several rat tissue types, although the 93 kDa band is restricted to the brain and gut. Western blotting of homogenates of rat brain and peripheral nerve revealed an additional band at 28 kDa. This 28 kDa band is not present in blots from embryonic hippocampal neurons, suggesting that the antigen may be associated with non-neuronal cells such as glia found in the brain and nerve tissue homogenates (see below). The proteins that were recognized by the AIG mAbs in . AIG antibodies bind to a commercially available idiotypic anti-GMl antibody. Two control supernatants (NS1 cm and EA1B1 mAb) and two putative anti-idiotypic AIG mAb supematants (AIG5 and AIG20) were tested in an ELISA assay for their ability to bind to a commercially available idiotypic anti-GMl polyclonal rabbit serum. The values from 10 ELISA assays were compared to control assays using rabbit serum. From a comparison of control and experimental values, a mean of the percent of specific binding was determined. AIG 5 binding to the idiotypic antibody was significantly better man NS1 cm, EA1B1 mAb or AIG20 (P < 0 05, Students t-test assuming unequal variance).
Western blots of embryonic hippocampal neurons ( Figure 5 ) can be immunoprecipitated from Triton-soluble membranes extracted from rat brain homogenates ( Figure 6 ). The 93, 66, and 45 kDa proteins were specifically precipitated by the antibodies. The 57 kDa protein was found in control precipitations suggesting that this protein binds to the Sepharose support used to precipitate the antigens. The 28 kDa protein mentioned above appears as a 25 kDa band in the immunoprecipitates from rat brain. This protein is precipitated by both AIG mAbs but not by the NS1 control. This protein has some endogenous peroxidase activity as shown by the faint band precipitated by AIG5 and labeled with control NS1 cm or in the absence of secondary antibody.
A bioassay determined the biological activity of AIG mAbs
Embryonic hippocampal neurons were placed on a simple adhesive substrate. The cell density and culture media were chosen to minimize cell contact and glial contamination. Either of these conditions can promote neurite outgrowth and modify the assay results. This assay is a measure of the ability of the antibodies to induce neurite initiation, a process vital to brain development and regeneration. The numbers of neurites were counted for all neurons with at least one process that is as long as the diameter of the cell body (approximately 10 \Lm). The numbers of neuritic processes from experimental cultures treated with AIG5 or AIG20 were compared to control cultures treated with an IgM immunoglobulin (EA1B1) which binds the neuronal surface, or with NS1 myeloma cell conditioned media. The mean number of processes for AIG5 and AJG20 treated neurons was significantly greater than the mean for those in the control cultures (Student's t-test; P < 0.05; Figure 7 ). These results indicate that the AIG mAbs promote neurite initiation from cultured embryonic hippocampal neurons.
Discussion
We have generated anti-idiotypic monoclonal antibodies to the ganglioside GM1 (AIG mAbs) in order to use these antibodies as a probe of GM 1 activity. Because anti-idiotypic antibodies mimic the functional binding sites of the original antigen, these antibodies enable us to look at the biochemistry and biology of ganglioside function. Anti-idiotypic antibodies are normally produced in low amounts for the purpose of balancing idiotypic and anti-idiotypic antibody production (Jerne, 1974). Therefore, to generate these antibodies we had to overcome two barriers. The first barrier was that gangliosides are self antigens which renders them poor immunogens. The second barrier was that anti-idiotypes are produced in low amounts, testing the limits of hybridoma technology. To overcome these obstacles, the normal immune response to the ganglioside GM1 was altered using an immunosuppression method to disrupt the normal regulation of the immune system. This method has been used to generate antibodies to poor immunogens with the added result of increasing anti-idiotypic antibody production (Matthew and Sandrock, 1987; M.J.Riggott and W.D.Matthew, unpublished observations) . This method, then, allowed us to generate idiotypic and anti-idiotypic mAbs using a single immunization paradigm. From the hybridomas generated, the anti-idiotypic antibodies were selected for their ability to meet the criteria characteristic of an anti-idiotypic antibody to GM1.
A crucial property the AIG mAbs possessed was the ability 584 to bind specifically to (3-CT, and this binding was competed by GM1. This result showed that these antibodies did indeed mimic GM1 properties. For both AIG5 and AIG20, binding to (3-CT was inhibited most strongly by GM1 although GTlb was also able to inhibit AIG5 binding. This property reflects the ability of (3-CT to bind gangliosides other than GM1 (Cuatrecases, 1973; Holmgren et al, 1973a,b; Hollenberg, 1974) . The fact that GTlb also blocks binding suggests that the ability to bind to the Gal(31-4Glc linked sialic acid common to GTlb may be an important component of the AIG5 epitope. This common epitope contrasts the more restricted GalNAc|31-4(NeuAc2-3)Gal(31^Glc epitope of AIG20 determined from the blocking experiments. In these tests, neither GM1 nor GTlb were able to completely block AIG mAb binding to (3-CT. We suspect that this is due to steric hindrance from the large size of the AIG mAb IgM molecules (~l,000 kDa) which may block the access of the small ganglioside molecules (GM1 -1.54 kDa) in these assays. It is also known that GM1 and GTlb differ in their critical micelle concentration, and their charge due to the presence of sialic acid each of which may influence the ability of these two different gangliosides to block AIG mAb binding. AIG mAb binding to 3-CT could not be reproduced by the control IgM immunoglobulins or the secondary antibody alone when NS1 myeloma cell conditioned media replaced a primary antibody.
The next test an anti-idiotypic antibody must pass is the ability to bind to an idiotypic anti-GMl antibody. Generally, the idiotypic antibody is used as the immunogen for the anti- idiotypic antibody and subsequently used to perform this test (Chanh et al, 1987; Saleh, 1993) . In the novel approach that we used to generate the AIG mAbs, the anti-idiotypic and idiotypic antibodies were generated concurrently in the same animal using GM1 as the immunogen. For this reason, a commercially available idiotypic anti-GMl antibody was used for these tests. The results showed that AIG5 binds to the idiotypic antibody more strongly than AIG20 or the control antibodies. This confirms that AIG5 is indeed an anti-idiotypic antibody, but does not eliminate AIG20 as an anti-idiotype. These results are consistent with the blocking experiments which suggest that AIG5 and AIG20 are generated to different epitopes of the GM1 antigen. Therefore, confirmation of the anti-idiotypic nature of AIG20 requires the use of an idiotypic anti-GMl antibody directed to the same epitope of GM1 as AIG20. This result foreshadows the finding that the AIG mAbs display different affinities for cellular proteins as described below. The AIG mAbs recognized several putative ganglioside binding proteins. Four bands were recognized by both AIG5 and AIG20 in Western blots of tissue homogenates and immunoprecipitations from a brain homogenate. Each antibody exhibits different affinities for the same protein consistent with the AIG mAb affinities for different GM1 epitopes. Earlier studies have shown that a single protein may bind with different affinities to several gangliosides (Higashi et al, 1981; Yamada et al, 1981; Zdebska et al, 1992) .
One of the proteins, the 57 kDa protein, was found in control precipitations, suggesting that this protein binds to a carbohydrate moiety of the Sepharose support used to precipitate the antigens. This result does not eliminate the 57 kDa protein as a ganglioside binding protein, however. The ability to bind carbohydrates is consistent with one of the properties of the ganglioside binding protein 3-CT which binds GM1 via the carbohydrate moiety on this ganglioside (Holmgren et al, 1973a,b) .
The proteins recognized by the AIG mAbs in the Western blots may be related to a previously identified GM1 binding protein recovered from rat brain using differential centrifugation (100 kDa; Siegel and Suzuki, 1994) , the known ganglioside binding protein serum albumin (66 kDa), or the 180/98, 57, and 45 kDa proteins identified in muscle extracts by Chan and Liu using Lucifer yellow CH labeled GM1 (Chan and Liu, 1991) . The 93 kDa protein is particularly intriguing because it is restricted to brain (this report) and skeletal muscle (Chan and Liu, 1991) . Labeling of intracellular membranes may reflect AIG mAb binding to the enzymes involved in ganglioside carbohydrate synthesis, which anti-idiotypic antibodies that mimic carbohydrate epitopes have been known to do (Matthew and Sandrock, 1987) . AIG mAb-labeled neuronal surfaces (shown here) suggests that the endogenous gangliosides enriched on the surface of these cells are co-localized with putative ganglioside binding proteins.
Our initial question was whether ganglioside binding to a membrane protein was sufficient to activate membrane proteins. From immunocytochemistry, we know that the AIG mABs, which model gangliosides, bind to the neuronal cell surface membranes. We have shown that when cultured neurons are incubated with the AIG mAbs, the neurons respond by increased neurite sprouting. Neurons in the presence of control IgM antibodies (EA1B1) are not affected, showing that the effect was not due to the binding of IgM immunoglobulins to the neuronal surface. This evidence suggests that the AIG mAbs, as well as gangliosides, can act by binding to and activating membrane proteins.
Ganglioside-protein interactions may be a key modulator of cellular growth and migration (Spirman et al, 1982; Bremer et al, 1984 Bremer et al, , 1990 Doherty et al, 1985; Cheresh and Klier, 1986; Cheresh et al, 1987; Stallcup, 1988; Tsuji et al, 1988 Tsuji et al, , 1992 Stallcup et al, 1989; Barletta et al, 1991; Nakaoka et al, 1992; Mutoh et al, 1995; Nagai, 1995) . Knowing that the AIG mAbs can mimic ganglioside activity in competitive binding assays, we have devised a testable model for ganglioside modulated neurite outgrowth. In this model, endogenous gangliosides can be mimicked experimentally by AIG mAbs to determine whether ganglioside stimulated neurite outgrowth is due to direct interaction of gangliosides with membrane proteins or whether gangliosides must intercalate into the cell surface membrane to exert their effects. The AIG mAbs are excellent probes to test this model of ganglioside activity and can be used to identify the proteins involved. The first test of this model shows that AIG mAbs stimulate sprouting of primary neurites in culture, supporting the hypothesis that GM1 acts by binding to and stimulating neuronal surface proteins.
Materials and methods

Generating monoclonal anti-idiotypic antibodies to gangliosides
Preparation of the immunogen. GM1 (3.5 mg, Sigma) was solubilized in 0.5 ml of absolute ethanol and added to 0.7 mg of glutaraldehyde activated glass beads (Affinity Adsorbent, 665-525, Boehringer Mannheim). The ethanol was evaporated under a stream of nitrogen gas so that the ganglioside is dried onto the surface of the glass bead. The beads act as an inert carrier to hold the ganglioside antigen in place during antigen presentation (Matthew, 1992) . For antigen presentation, the beads were suspended in 7.0 ml of RPMI-1640 culture medium.
Immunizations. Female BALB/c mice (Charles River) 8 weeks old received a 1 ml volume of bead suspension i.p. containing 0.5 mg of ganglioside on days 0 and 14. Four different cyclophosphamide regimes were used: cyclophosphamide (2 mg/ml in saline) was given i.p. at a dose of 100 mg/kg and/or 150 mg/kg at 10 min after the first immunization and/or 24 h later.
Preparation of antibodies. Spleen cells of immunized mice were fused with NS1 myeloma cells on day 17 (as described in Matthew and Sandrock, 1987, and Dunbar and Skinner, 1990) .
Screening of antibodies
The antibodies were screened in solid-phase enzymelinked immunosorbent assays (ELISAs) and dot blot assays (Ausubel et al., 1990) . Gangliosides and galactocerebroside were solubilized in methanol at a concentration of 10 (xg/ml. One hundred microliters was pipetted into each well of a 96 well ELJSA plate and the solvent evaporated in a fume hood. The fi-subunit of cholera toxin (B-CT, Sigma) or extracts of dissociated rat embryonic hippocampal cells were prepared in 0.05 M Tns buffered saline (TBS); 100 u.1 was pipetted into each well of a % well ELISA plate or dot blot apparatus and allowed to adsorb for 2 h at room temperature or overnight at 4°C. Assays were performed and analyzed as described previously (Miyoshi et al., 1982; Matthew and Sandrock, 1987) . Briefly, the substrates were washed with 1% polyvinylpyrrolidone-360 kDa (Sigma) made up in TBS, pH 7.4 (PVP/TBS), and 100 u.1 of hybridoma supernatant or NS1 conditioned media was added to each well. After 1 h of incubation, the wells were washed. In blocking experiments designed to test whether antibody binding to the p-subunit of cholera toxin could be blocked selectively by gangliosides, 50 u.1 of GM1, GM2, GM3, GDla, GDlb, or GTlb (a gift from Fidia Pharmaceutical Company, Abano Terme, Italy) (100 g/ml -I ng/ml) in TBS was incubated for 2 h at 37°C (adapted from Schengrund and Ringler, 1989) . Twenty-five microhters was removed and 25 u.1 of purified anti-idiotypic antibody or control antibody (400 u,g/ml protein in PBS) was incubated in the wells for 1 h at room temperature. The wells were washed and incubated with HRP-conjugated antimouse immunoglobulins. The complex was visualized in ELISA assays by the addition of p-phenylene-diamine (PPDA; EM Science) and in dot blot assays with 3,3' diaminobenzidine (DAB, Sigma) with hydrogen peroxide in TBS (Ausubel et al.. 1990 ) ELISA reactions were stopped by the addition of IN HC1 and the absorbance was measured at 405 nM using a Bio-Tek Instruments EIA Reader. The antibodies were then isotyped using a Mouse Monoclonal Sub-Isotyping Kit (Hyclone Labs, Inc.)
Anti-idiotypic GM1 antibodies were also tested for their ability to bind to lipid and protein extracts of rat brain tissue. Lipids were separated from proteins using a chloroform-methanol (1:1) extraction of Folch et al. (1957) modified by Freyburger et al. (1988) . Briefly, I ml of brain homogenate in TBS was added to 2 ml of chloroform plus 2 ml methanol and shaken vigorously. The solution was centnfuged at 2000 x g for 5 min to elicit phase separation. The lower chloroform phase containing the lipids was recovered and pooled with the lower phase of a second extract of the upper aqueous phase. Lipids in the chloroform phase were dried under nitrogen gas, resuspended in methanol and then dried onto ELISA plates. Brain proteins from the methanol phase were adsorbed onto ELISA plates by air drying overnight in a sterile hood Anti-idiotypic antibody labeling was performed as described above.
To confirm that the antibodies were anti-idiotypic for GM1, the antibodies were tested for their ability to bind to a commercially available idiorypic anti-GMl antibody. To do this, a sandwich ELISA was used. Rat anti-mouse IgM immunoglobulins were adsorbed to ELISA plates, washed, and incubated with anti-idiotypic antibodies, control IgM antibodies or NS1 conditioned media (all anti-idiotypic antibodies tested were IgM). After washing, the wells were incubated with rabbit ldiotypic anti-GMl IgG (Matreya, Inc.) for 1 h at room temperature, washed and incubated with HRP-conjugated rabbit antiIgG. The complex was visualized by the addition of PPDA and hydrogen peroxide in TBS (Ausubel et al., 1990) .
Distribution and identification of antigens of interest
Preparation of dissociated hippocampal neurons. Hippocampi were dissected from embryonic day 18 rats. The meninges were removed and the cells were incubated at 37°C in Ca 2+ ,Mg 2+ -free Hanks' buffered salt solution (HBSS) with 0.005% (w/v) trypsin for 15 min. The cells were washed in DMEM/F12 media with 5% horse serum and 2.5% calf serum and triturated. The cells were spun and resuspended in opti-MEM with N2 additives (Gibco) and 60 pM basic fibroblast growth factor (bFGF, Collaborative Biochemical Products) to a final concentration of 0.5-2 x 10 5 cells/ml and plated on poly-lysine coated 35 mm dishes (adapted from Banker and Cowan, 1977; Banker and Goshn, 1991) .
Immunocytochemistry of tissues sections. Young adult rats were anesthetized with a cocktail (2 ml/kg body weight of 50 mg/ml ketamine, 2.6 mg/ml xylazine, 0.5 mg/ml acepromozine) and decapitated, and tissue was removed for immunocytochemistry or biochemistry (see below). The tissue was frozen onto chucks in dry ice, equilibrated to -15°C, and cut onto subbed slides. The 15 u.m sections were washed with 10% FCS in Tris-buffered saline pH 7.4 (FCS/ TBS), incubated with hybridoma supernatant overnight at 4°C, washed with 10% calf serum in Tris-buffered saline pH 7.4 (CS/TBS), incubated with fluorescein-coupled goat anti-mouse immunoglobulins (Antibodies Inc.) for I h at room temperature, washed with CS/TBS and TBS, coverslipped with Vectashield (Vector Labs), and viewed using fluorescent optics.
Molecular identity of antigens recognized by the anti-idiotypic antibodies.
Rat embryonic hippocampal cells, brain tissue, peripheral nerve, gut, skeletal muscle, or human hippocampus was homogenized in TBS and boiled in sample buffer with SDS and mercaptoethanol. Proteins were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose paper. The blot was blocked with 1% PVP/TBS, incubated with hybridoma supernatant, washed with CS/TBS, and incubated with HRP-conjugated anti-mouse IgM. The bound antibody was visualized using DAB (Ausubel et al., 1990) Immunoprecipitation of antigens. A method closely following that of Kapnelian and Patterson (Kaprielian and Patterson, 1993) was used. Briefly, a young rat was anesthetized as described above, and decapitated The brain was removed and homogenized in TBS with 5 mM EDTA, 2 mM EGTA, and the following proteases: 1 mM PMSF, 20 u,g/ml aprotinin, 20 u.g/ml turkey egg white trypsin inhibitor, 2 mM benzamide, and 5 mM N-ethylmaleimide. The homogenate was spun at 1000 x g for 10 min to pellet nuclei, mitochondria, and cell debris. The supernatant was spun at 100K x g for 1 h at 4°C for 1 h All further centnfugation steps were carried out at 100K x g for 1 h at 4°C for 1 h. The pellet was washed two times in homogenization buffer by centrifugation and resuspension The final pellet contained the membrane/cytoskeletal fraction. This fraction was solubilized in 1%-Triton X-100, and centnfuged to separate the soluble fraction containing membrane proteins from cytoskeletal and other insoluble proteins.
Tnton X-100 soluble membranes were incubated in the presence of hybndoma supernatant or NS1 conditioned media. Following incubation with antimouse immunoglobulins, the antibody binding proteins were bound to protein G-sepharose and separated by low speed centnfugation. The beads bound to the membrane proteins via the antibodies, were washed and then the proteins were solubilized in 2x sample buffer The proteins were separated by SDS-PAGE and blotted onto nitrocellulose. The blots were probed with AIG mAbs to identify the antigens that were recovered by immunoprecipitation.
In vitro axon outgrowth bioassay
Culture methods for dissociated hippocampal neurons. Hippocampi were dissected from embryonic day 18 rats. The meninges were removed and the cells were incubated at 37°C in Ca 2+ ,Mg 2+ -free Hanks' buffered salt solution (HBSS, Gibco) with 0.005% (w/v) trypsin for 15 min. The cells were washed in DMEM/F12 media (Gibco) with 5% horse serum and 2.5% calf serum and triturated. The cells were spun and resuspended in opti-MEM with N2 additives (Gibco) and 60 pM bFGF (Collaborative Biochemical Products) to a final concentration of 0.5-2 x 10 5 cells/ml and plated on poly-lysine coated 35 mm dishes (adapted from Banker and Cowan, 1977; Banker and Goslin, 1991) .
Labeling neurons in culture. Dissociated cells were plated onto glass chamber slides coated with poly-L-lysine (Sigma). The cells were allowed to grow until neurites formed (1-3 days). Cultures were fixed with 4% paraformaldehyde and some were permeabilized with 0.3% Triton X-100 to allow labeling of intracellular structures. The slides were washed with medium, incubated with hybridoma supernatant for 1 h, washed with 1% PVP/TBS or 2.5% calf serum in Tris-buffered saline pH 7.4 (CS/TBS), incubated with fluorescein-coupled goat anti-mouse immunoglobulins (Antibodies Inc.) for 1 h, washed with CS/ TBS and TBS, coverslipped with Vectashield (Vector Labs), and then viewed using a fluorescence microscope.
Bioassays. Dissociated cells were plated onto poly-L-lysine coated glass coverslips (Banker and Cowan, 1977; Banker and Goslin, 1991) in the presence of an equal volume of hybridoma supernatant, control IgM monoclonal antibodies (EA1B1 for experiments using embryonic hippocampal neurons) or NS1 conditioned media. Control antibodies were of the same immunoglobulin class as the AIG antibodies (IgM) and bind to the surface of the neurons tested. The final serum concentration in these assays was 5%, and the growth factor final concentration was 30 pM bFGF. Neurons were cultured for 2 days at a low density to prevent aggregate formation and yet provide a large number of healthy cells for observation in control and experimental conditions After this time, in the absence of glial or feeder cells, the number of healthy neurons in the control cultures is dramatically reduced. Living cells incorporated the vital dye 6-carboxyfluorescein diacetate succinimidyl ester (CF; Rotman and Papermaster, 1966; Bronner-Fraser, 1985) and then were fixed with 2% paraformaldehyde and observed with fluorescent optics Measuring the extent ofneurite outgrowth. Neuronal soma and their processes were filled entirely with the CF dye, and the neurons were easily identified by their morphology. Images were collected of all neurons in the culture dishes using the Image 1 image analysis system and a silicon intensified (SIT) camera to prevent bleaching of the dye from overexposure to light. Only images of those neurons that did not contact other cells in the culture were used for analysis. The number of neurites was measured from neurons with at least one process that was as long as the diameter of the soma (approximately 10 ji.m) The numbers of processes and branches were noted.
